Assessment of drug incorporation and release from a novel coronary stent coating

Craig Martin McKittrick, Simon Dixon, Christopher McCormick

Research output: Contribution to conference › Poster

Abstract

The introduction of drug eluting stents (DES) for the treatment of coronary heart disease has significantly reduced in-stent restenosis, however the use of cytostatic agents causes delayed re-endothelialisation of the target vessel. Here we describe the drug release profiles for rapamycin incorporated into a novel acrylic-based polymer designed to promote vascular re-endothelialisation. Understanding drug release from the surface of DES is integral to the stent development process. It is useful for testing the reliability and reproducibility of coatings and for providing insight into mechanisms of drug release.
LanguageEnglish
Publication statusPublished - 30 Aug 2015
Event27th European Conference on Biomaterials - ICE Krakow Congress Centre, Krakow, Poland
Duration: 30 Aug 2015 → 3 Sep 2015

Conference

Conference27th European Conference on Biomaterials
Abbreviated titleESB 2015
CountryPoland
CityKrakow
Period30/08/15 → 3/09/15

Fingerprint

Stents
Drug-Eluting Stents
Coatings
Cytostatic Agents
Sirolimus
Coronary Disease
Blood Vessels
Polymers
Acrylics
Drug Liberation
Testing

Keywords

  • drug delivery
  • drug release
  • coronary stent coating
  • drug eluting stents
  • DES

Cite this

McKittrick, C. M., Dixon, S., & McCormick, C. (2015). Assessment of drug incorporation and release from a novel coronary stent coating. Poster session presented at 27th European Conference on Biomaterials , Krakow, Poland.
McKittrick, Craig Martin ; Dixon, Simon ; McCormick, Christopher. / Assessment of drug incorporation and release from a novel coronary stent coating. Poster session presented at 27th European Conference on Biomaterials , Krakow, Poland.
@conference{344b80eb95fa412189a7760e8d9f5f27,
title = "Assessment of drug incorporation and release from a novel coronary stent coating",
abstract = "The introduction of drug eluting stents (DES) for the treatment of coronary heart disease has significantly reduced in-stent restenosis, however the use of cytostatic agents causes delayed re-endothelialisation of the target vessel. Here we describe the drug release profiles for rapamycin incorporated into a novel acrylic-based polymer designed to promote vascular re-endothelialisation. Understanding drug release from the surface of DES is integral to the stent development process. It is useful for testing the reliability and reproducibility of coatings and for providing insight into mechanisms of drug release.",
keywords = "drug delivery, drug release, coronary stent coating, drug eluting stents, DES",
author = "McKittrick, {Craig Martin} and Simon Dixon and Christopher McCormick",
year = "2015",
month = "8",
day = "30",
language = "English",
note = "27th European Conference on Biomaterials , ESB 2015 ; Conference date: 30-08-2015 Through 03-09-2015",

}

McKittrick, CM, Dixon, S & McCormick, C 2015, 'Assessment of drug incorporation and release from a novel coronary stent coating' 27th European Conference on Biomaterials , Krakow, Poland, 30/08/15 - 3/09/15, .

Assessment of drug incorporation and release from a novel coronary stent coating. / McKittrick, Craig Martin; Dixon, Simon; McCormick, Christopher.

2015. Poster session presented at 27th European Conference on Biomaterials , Krakow, Poland.

Research output: Contribution to conference › Poster

TY - CONF

T1 - Assessment of drug incorporation and release from a novel coronary stent coating

AU - McKittrick, Craig Martin

AU - Dixon, Simon

AU - McCormick, Christopher

PY - 2015/8/30

Y1 - 2015/8/30

N2 - The introduction of drug eluting stents (DES) for the treatment of coronary heart disease has significantly reduced in-stent restenosis, however the use of cytostatic agents causes delayed re-endothelialisation of the target vessel. Here we describe the drug release profiles for rapamycin incorporated into a novel acrylic-based polymer designed to promote vascular re-endothelialisation. Understanding drug release from the surface of DES is integral to the stent development process. It is useful for testing the reliability and reproducibility of coatings and for providing insight into mechanisms of drug release.

AB - The introduction of drug eluting stents (DES) for the treatment of coronary heart disease has significantly reduced in-stent restenosis, however the use of cytostatic agents causes delayed re-endothelialisation of the target vessel. Here we describe the drug release profiles for rapamycin incorporated into a novel acrylic-based polymer designed to promote vascular re-endothelialisation. Understanding drug release from the surface of DES is integral to the stent development process. It is useful for testing the reliability and reproducibility of coatings and for providing insight into mechanisms of drug release.

KW - drug delivery

KW - drug release

KW - coronary stent coating

KW - drug eluting stents

KW - DES

UR - http://www.esbiomaterials.eu/

M3 - Poster

ER -

McKittrick CM, Dixon S, McCormick C. Assessment of drug incorporation and release from a novel coronary stent coating. 2015. Poster session presented at 27th European Conference on Biomaterials , Krakow, Poland.

Access to Document

    Related content

    Projects

    Optimal designs of drug eluting stents

    Project: Research